ALS is almost always fatal. No cure exists, and the disease progressively destroys the nerve cells that control voluntary movement, eventually affecting the ability to breathe, swallow, and move. Median survival from symptom onset ranges from 20 to 36 months in population-based studies. But that number obscures meaningful variation: 5 to 10% of people with ALS survive longer than 10 years, and a small number of verified cases have shown genuine disease reversal.
How ALS Causes Death
Respiratory failure is the primary cause of death, accounting for about 25% of deaths where ALS is listed on the death certificate. As the disease progresses, the muscles responsible for breathing weaken until they can no longer inflate the lungs adequately. This can also set the stage for pneumonia and aspiration, where food or stomach contents enter the airways because the swallowing muscles have lost strength. Cardiovascular disease is the second most common co-occurring cause of death, appearing in roughly 13% of ALS death records.
Difficulty swallowing also contributes directly. When swallowing becomes unreliable, maintaining adequate nutrition gets harder. Malnutrition and dehydration accelerate decline and reduce the body’s ability to fight infection. These complications are not inevitable at any single point in the disease, but they accumulate as motor neurons continue to die.
What Determines How Long Someone Lives
Several clinical factors shape the timeline. Age at onset is one of the strongest predictors: younger patients tend to progress more slowly. Where symptoms first appear also matters. People whose disease begins in the limbs generally have a longer course than those who first lose speech or swallowing function, though the pattern is not absolute. Body weight at diagnosis plays a role too. Higher BMI at the time of diagnosis is associated with slower progression.
Genetics add another layer. A large study comparing patients with very short survival (under 15 months) to those with very long survival (over 100 months) found striking genetic differences. Mutations in the C9orf72 gene and the FUS gene appeared only in fast progressors. SOD1 gene variants, by contrast, showed up in both groups but accounted for 75% of identifiable genetic causes among slow progressors and only 33% among fast progressors. In other words, the specific genetic variant driving someone’s ALS can dramatically shift their outlook.
Treatments That Extend Survival
No available treatment stops ALS, but several interventions meaningfully extend life. The most widely used medication adds an average of 2 to 3 months of survival, which translates to roughly a 9% increase in one-year survival. That sounds modest, and it is, but it reflects the limited options available since the drug’s approval in the mid-1990s.
Specialized multidisciplinary ALS clinics, where neurologists, respiratory therapists, nutritionists, speech therapists, and physical therapists coordinate care, have a larger measurable impact. One population-based study found that patients treated at a dedicated ALS clinic had a median survival 7.5 months longer than those seen by general neurologists. One-year mortality dropped by nearly 30%. This benefit comes not from any single intervention but from the combined effect of managing breathing, nutrition, mobility, and communication in a coordinated way.
Nutritional support through a feeding tube placed in the stomach (a PEG tube) also plays a significant role. For patients who can no longer safely swallow enough calories, a feeding tube maintains body weight and reduces the risk of aspiration. Studies show that patients who gain arm muscle mass in the first three months after tube placement have measurably longer survival, with each centimeter of muscle circumference gained lowering the risk of death by about 10 to 11%. The benefit appears especially strong in patients with bulbar-onset ALS, who had a 55% lower risk of death after tube placement compared to those with limb-onset disease.
Ventilation Can Add Years
Breathing support is the single most powerful tool for extending life with ALS. Non-invasive ventilation, delivered through a mask, helps when the breathing muscles begin to weaken. It improves quality of life and extends survival, with a median of about 15 months from the start of ventilation.
Invasive ventilation through a tracheostomy, a surgical opening in the windpipe connected to a mechanical ventilator, can extend life far longer. In a 12-year national study from Norway, median survival on tracheostomy ventilation reached 74.8 months, or just over six years. Some patients lived beyond nine years on this support. The tradeoff is significant: tracheostomy ventilation requires round-the-clock care, limits communication, and fundamentally changes daily life. Some people choose it; many do not. Both are reasonable decisions.
The Rare Exceptions
A small but real number of ALS patients experience something unexpected: their disease stops progressing or partially reverses. Researchers at a major ALS reversal study have independently verified 34 cases so far through medical records and published literature. These are not misdiagnoses. These are people who met diagnostic criteria for ALS and then improved in ways the disease does not typically allow.
The leading hypothesis is genetic. These patients may carry protective genetic variants that confer a form of disease resistance, allowing their motor neurons to survive or recover in ways that most ALS patients’ neurons cannot. Research into these cases is ongoing, and the numbers are tiny compared to the roughly 30,000 Americans living with ALS at any given time. But they challenge the absolute statement that ALS is always fatal.
It is also worth distinguishing ALS from a related condition called primary lateral sclerosis, or PLS. PLS affects only the upper motor neurons, progresses much more slowly, and is not necessarily life-shortening. Most people with PLS live a typical lifespan. Early in the disease, PLS and ALS can look similar, and some people initially diagnosed with PLS are later reclassified as having ALS if lower motor neurons become involved. This diagnostic overlap is one reason some people encounter conflicting information about whether motor neuron diseases are universally fatal.
What the Numbers Mean in Practice
For the vast majority of people diagnosed with ALS, the disease will shorten their life. That is the honest answer. But “always fatal” oversimplifies a condition with real variability. A 25-year-old with a slow-progressing SOD1 variant, access to a multidisciplinary clinic, and willingness to use ventilation support faces a very different trajectory than a 70-year-old with bulbar-onset disease and a C9orf72 expansion.
The median survival of 20 to 36 months reflects the population average, but individual experience spreads widely around that number. Roughly 1 in 10 to 1 in 5 patients lives beyond a decade. Coordinated care, nutritional support, and breathing assistance all shift the timeline in measurable ways. And for a handful of patients, the disease defies its own reputation entirely.